Retatrutide
Also known as · LY3437943 · Triple-G
to clear
How a single dose clears, assuming first-order elimination. The half-life is the biggest driver of how often you dose — start a cycle to see your own cumulative concentration curve.
An investigational triple agonist (GIP/GLP-1/glucagon) showing the largest weight-loss figures yet in trials. Not yet approved.
Activates GIP, GLP-1, and glucagon receptors, adding energy-expenditure effects to appetite suppression.
Weekly subQ; trial titration from 1 mg up to ~12 mg.
Refrigerated; protect from light.
This page summarizes publicly available information. None of it constitutes medical advice, prescription, or recommendation to acquire, possess, or use any compound. Many peptides described are research chemicals not approved for human use in the EU. Consult a licensed physician.
Semaglutide
A long-acting GLP-1 receptor agonist for type-2 diabetes and weight management. Slows gastric emptying and suppresses appetite.
Tirzepatide
A dual GIP/GLP-1 receptor agonist with superior weight loss and glycemic control versus semaglutide in head-to-head trials.
Cagrilintide
A long-acting amylin analog studied for weight loss, often paired with semaglutide (CagriSema).